Paper Details

  1. Home
  2. Paper Details

[Update on new antithrombotic treatments].

Author: BoehlenF, FontanaP, Tirefort-DimitrovaY, de MoerlooseP

English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This article provides an update on new antithrombotic treatments, highlighting the emergence of new anticoagulants like fondaparinux, rivaroxaban, and dabigatran. It also discusses new antiplatelet agents like prasugrel, ticagrelor, and cangrelor, emphasizing the need for individualized prescriptions due to their varying bleeding risks and side effects.
Paper Details　
Original Abstract of the Article :
Update on new antithrombotic treatments Antithrombotic treatments are frequently prescribed in different clinical situations. Classical anticoagulants have some disadvantages. New anticoagulants have emerged recently. Fondaparinux is now prescribed for both prophylaxis and treatment of venous thromb...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/20170027

データ提供：米国国立医学図書館（NLM）

Navigating the Shifting Sands of Antithrombotic Treatment

Antithrombotic medications play a critical role in preventing blood clots, which can be a serious health concern. Traditional anticoagulants have been used for many years, but they can have drawbacks. This research reviews new antithrombotic treatments that have emerged in recent years, offering hope for more effective and safer options.

New Antithrombotic Agents: A Review

This review summarizes recent advancements in antithrombotic therapy, highlighting novel agents like fondaparinux, rivaroxaban, and dabigatran. The research also explores new antiplatelet agents targeting the P2Y12 receptor and other pathways. This review provides an up-to-date overview of the current landscape of antithrombotic medications, offering valuable insights for clinicians.

A New Era of Personalized Antithrombotic Treatment

This review suggests that the development of new antithrombotic agents has the potential to revolutionize the field of thrombosis management. These new medications offer greater specificity and personalized treatment options. Just like a camel adapts to the diverse terrain of the desert, these new therapies are tailored to meet the unique needs of individual patients.

Dr.Camel's Conclusion

This review provides a fascinating glimpse into the evolving landscape of antithrombotic treatment. It highlights the potential of these new medications to improve patient outcomes and create a more personalized approach to managing blood clots.
Date :
  1. Date Completed 2010-05-04
  2. Date Revised 2010-02-22
Further Info :

Pubmed ID

20170027

DOI: Digital Object Identifier

20170027

Related Literature

Article Analysis
・Side Effects of prasugrel
SNS
PICO Info
in preparation
Languages

French

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.